Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Mirion Technologies, Inc. (symbol: MIR) is a leading provider of radiation detection, measurement, analysis, and monitoring products and services. Mirion serves a diverse range of markets including nuclear power, medical, military, and homeland security, ensuring the safety of people, property, and the environment from nuclear and radiological hazards for over 50 years.
Headquartered in the San Francisco Bay Area, Mirion operates facilities across Europe, Asia, and North America, making it a globally recognized entity in the realm of radiation safety solutions. The company is structured into two main segments:
- Medical Segment: This segment focuses on radiation oncology quality assurance, providing critical patient safety solutions in diagnostic imaging and radiation therapy centers. Mirion’s advanced technologies ensure precise and reliable results, significantly enhancing patient care and safety.
- Technologies Segment: Catering to nuclear energy, defense, laboratories, scientific research, and other industrial markets, this segment represents the largest portion of the company’s revenue. Mirion's products and services in this segment are vital for accurate measurement and analysis in high-stakes environments, contributing to scientific advancements and industrial safety.
Mirion Technologies’ recent achievements include the development of cutting-edge radiation detection tools and strategic partnerships aimed at enhancing global safety standards. The company’s commitment to innovation is underscored by its continuous investment in R&D, resulting in reliable and advanced products that meet the evolving needs of its diverse clientele.
Financially, Mirion Technologies has demonstrated solid performance, with a robust revenue stream primarily driven by the Technologies segment. The company’s global presence, coupled with its specialized expertise, positions it as a critical player in the fields it serves.
Mirion Technologies, Inc. (NYSE: MIR) announces the appointment of Dr. Sheila Rege, M.D. to its Board of Directors, succeeding Mr. Christopher Warren. Dr. Rege, a board-certified radiation oncologist with over 30 years of experience, will support Mirion's strategy to enhance its Medical segment, aiming for 50% of total revenue. Chairman Lawrence D. Kingsley expressed confidence in her contributions to the company’s growth. Chris Warren leaves with commendations for his role in Mirion's evolution since 2015, emphasizing strong demand momentum in the market.
Sun Nuclear, a subsidiary of Mirion Technologies (NYSE: MIR), announced that its ATOM® Phantom product line will participate in NASA's historic Artemis I mission, set to launch on August 29, 2022. Two custom ATOM Phantoms, named Helga and Zohar, will measure potential radiation exposure for astronauts aboard the Orion spacecraft. This mission marks an important step for human exploration of the Moon and Mars. The ATOM Phantoms, designed to simulate human anatomy, will assist in understanding the effects of space radiation, particularly on female astronauts.
Mirion Technologies (NYSE: MIR) has completed the acquisition of the Critical Infrastructure business from Collins Aerospace, specifically through its subsidiary ARINC Incorporated. This acquisition aims to enhance Mirion's capabilities in command-and-control software solutions, particularly for nuclear power facilities and government security. The new division, branded as Secure Integrated Solutions (SIS), is expected to bolster Mirion's digital solutions for its industrial clients, leveraging the expertise of the acquired team in software development.
Mirion Technologies, Inc. (NYSE: MIR) reported a 2.3% decline in second-quarter revenues to $175.8 million, with a net loss of $59.3 million. Adjusted EBITDA fell 14.6% to $42.6 million, and adjusted EPS was $0.13. The company confirmed its 2022 expectations for organic adjusted revenue growth of 4%-6% and adjusted EBITDA of $170-$180 million. Order growth reached 25% in the first half, with a backlog of $693 million, despite a $55 million impairment due to project cancellations related to the Russia-Ukraine conflict.
Mirion Technologies, Inc. (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at the Jefferies Industrials Conference in New York, NY, on Wednesday, August 10, 2022, at 1:00 PM ET. The presentation will be available via a live webcast, which can be accessed on their website under the 'Events and Presentations' section. An archived version will be posted within 12 hours post-event and will remain accessible for at least two weeks. Mirion specializes in detection and monitoring solutions across various end markets.
Mirion Technologies, Inc. (NYSE: MIR) will release its financial results for the second quarter of 2022 on Friday, July 29, 2022. The company will hold a conference call at 10:00 am ET to discuss these results. Interested participants can join the call by dialing 1-877-407-9208 or 1-201-493-6784. A live webcast will also be available on the Mirion investor relations website. A telephonic replay will be accessible until August 12, 2022.
Mirion Technologies (NYSE: MIR) has announced the rebranding of its Medical segment to the Mirion Medical group, consolidating its healthcare-focused entities like Dosimetry Services and Sun Nuclear. This move aims to leverage expertise in ionizing radiation for healthcare applications, enhancing safety and efficiency for practitioners and patients. The new brand identity will feature a family logo, indicating unity among the different business units. This change will not affect how Mirion reports financial performance externally.
Mirion Technologies, Inc. (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at CJS Securities’ 22nd Annual “New Ideas” Summer Conference in Greenwich, CT, on Tuesday, July 12, 2022. Mirion is a leader in detection, measurement, and monitoring solutions for the nuclear, defense, medical, and research sectors, emphasizing regulatory compliance and operational excellence. The company is headquartered in Atlanta, GA, and employs approximately 2,600 individuals across 13 countries.
Sun Nuclear Corporation, a subsidiary of Mirion Technologies (NYSE: MIR), will showcase its advanced quality management solutions for radiation therapy at the ESTRO 2022 Congress from May 6-10 in Copenhagen. Key highlights include the introduction of the SunSCAN™ 3D Cylindrical Water Scanning System, which enhances workflow efficiency and accuracy for stereotactic treatments. The SunCHECK™ Platform introduces a new SaaS option for easier deployment. Sun Nuclear also integrates CIRS technology for patient safety, with product demonstrations and educational sessions scheduled throughout the event.
Mirion Technologies, Inc. (NYSE: MIR) reported a 1.8% decrease in revenues for Q1 2022, totaling $163.2 million. The net loss improved to $19.0 million from $40.7 million year-over-year. Adjusted EBITDA fell 12.5% to $34.9 million. The company updated its 2022 guidance, forecasting organic adjusted revenue growth of 4%-6% and adjusted EBITDA of $170-$180 million. Despite challenges from supply chain issues and the Ukraine conflict, Mirion remains optimistic about its business strategy and order inflows.
FAQ
What is the current stock price of Mirion Technologies (MIR)?
What is the market cap of Mirion Technologies (MIR)?
What does Mirion Technologies do?
Where is Mirion Technologies headquartered?
What are the main segments of Mirion Technologies?
What markets does the Technologies segment serve?
Which segment generates the most revenue for Mirion Technologies?
How long has Mirion Technologies been in operation?
In which regions does Mirion Technologies have facilities?
What is the focus of the Medical segment?
What recent achievements has Mirion Technologies made?
How does Mirion Technologies contribute to scientific research?
